Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Status:
Completed
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
The goal of the Phase I part of this clinical research study is to find the highest tolerable
dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with
interferon alfa-2b in patients with advanced or metastatic melanoma. The safety of this
combination will also be studied.
The goal of Phase II is to learn if this study drug combination can help to control advanced
or metastatic melanoma.